Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Sterile Injectable Manufacturing: SOP for Risk Assessment in Injectable Manufacturing – V 2.0

Posted on By

Sterile Injectable Manufacturing: SOP for Risk Assessment in Injectable Manufacturing – V 2.0

Standard Operating Procedure for Risk Assessment in Injectable Manufacturing

Department Sterile Injectable Manufacturing
SOP No. SOP/SIM/085/2025
Supersedes SOP/SIM/085/2022
Page No. Page 1 of 14
Issue Date 18/06/2025
Effective Date 20/06/2025
Review Date 18/06/2026

1. Purpose

This SOP provides a systematic approach to risk assessment in sterile injectable manufacturing. It ensures potential risks to product quality, patient safety, and regulatory compliance are proactively identified, analyzed, mitigated, and documented using scientific and process-based rationale.

2. Scope

This SOP applies to all critical operations, processes, equipment, materials, utilities, and documentation systems used in the sterile injectable manufacturing facility.

3. Responsibilities

  • Department Heads: Identify areas and processes requiring risk assessment.
  • QA Representative: Facilitate and coordinate risk assessment activities.
  • Risk
Assessment Team: Participate in risk evaluation and develop mitigation strategies.
  • QA Manager: Review and approve the risk assessment report and actions.
  • 4. Accountability

    The Head – Quality Assurance is accountable for ensuring compliance with this SOP and the effective execution of risk assessment procedures across all sterile injectable operations.

    5. Procedure

    5.1 Risk Assessment Planning

    1. Define the purpose and scope of the risk assessment (e.g., new equipment, process change, deviation analysis, etc.).
    2. Appoint a cross-functional team comprising QA, Production, Engineering, QC, and Regulatory Affairs.
    3. Prepare a Risk Assessment Plan (Annexure-1).

    5.2 Risk Identification

    1. Use tools such as Process Flow Diagrams, Cause-and-Effect (Fishbone) Diagrams, and Brainstorming sessions.
    2. Document all potential hazards, failure points, or deviations from predefined quality attributes or process parameters.
    3. Record identified risks in the Risk Register (Annexure-2).

    5.3 Risk Analysis

    1. Analyze the severity (S), probability (P), and detectability (D) of each risk using a scoring scale (e.g., 1–5).
    2. Calculate Risk Priority Number (RPN): RPN = S × P × D.
    3. Rank risks based on RPN value.

    5.4 Risk Evaluation and Control

    1. Classify risks as Low, Medium, or High based on predefined RPN thresholds.
    2. Determine appropriate control actions:
      • Elimination of the risk source
      • Substitution with a safer method
      • Implementation of engineering or administrative controls
    3. Record mitigation strategy in Risk Control Sheet (Annexure-3).

    5.5 Risk Mitigation and Implementation

    1. Assign responsible personnel and deadlines for risk mitigation actions.
    2. Monitor implementation progress.
    3. Verify effectiveness through impact assessments or validation reports.

    5.6 Risk Review and Approval

    1. Compile a Risk Assessment Report summarizing the process, findings, mitigation measures, and outcomes (Annexure-4).
    2. QA reviews and approves the final document.
    3. Maintain records for audit and regulatory submission.

    6. Abbreviations

    • SOP: Standard Operating Procedure
    • QA: Quality Assurance
    • RPN: Risk Priority Number
    • FMEA: Failure Mode and Effects Analysis
    • PFD: Process Flow Diagram

    7. Documents

    1. Risk Assessment Plan – Annexure-1
    2. Risk Register – Annexure-2
    3. Risk Control Sheet – Annexure-3
    4. Risk Assessment Report – Annexure-4

    8. References

    • ICH Q9 – Quality Risk Management
    • WHO TRS 986 Annex 2 – GMP Guidelines
    • ISO 31000: Risk Management – Principles and Guidelines

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation Manufacturing Executive QA Executive Head QA
    Department Production Quality Assurance Quality Assurance

    11. Annexures

    Annexure-1: Risk Assessment Plan

    Area Filling Line (SVP)
    Purpose New Equipment Installation
    Date 01/06/2025
    Team Members Sunita Reddy, Rajesh Kumar, Anita Mehta

    Annexure-2: Risk Register

    Risk ID Description Severity Probability Detectability RPN
    R001 Power failure during filling 5 4 3 60

    Annexure-3: Risk Control Sheet

    Risk ID Control Strategy Owner Deadline Status
    R001 UPS system installation Engineering 15/06/2025 Completed

    Annexure-4: Risk Assessment Report

    Report No. RAR/2025/015
    Summary Risk assessment conducted for SVP filling line installation. One high-risk and two medium-risk issues identified and mitigated. No unacceptable risk remains.
    Approved By QA Head
    Approval Date 16/06/2025

    Revision History

    Revision Date Revision No. Details Reason Approved By
    01/01/2022 1.0 Initial Issue New SOP QA Head
    18/06/2025 2.0 Revised structure, updated annexures Periodic Review QA Head
    See also  Sterile Injectable Manufacturing: SOP for Validation of Analytical Testing Methods - V 2.0
    Injectables V 2.0 Tags:Aseptic processing SOP, Aseptic technique in sterile manufacturing, Cleanroom SOP for injectables, SOP for ampoule sealing, SOP for autoclave sterilization, SOP for container closure integrity testing, SOP for environmental monitoring in aseptic area, SOP for gowning in cleanroom, SOP for in-process checks in sterile manufacturing, SOP for injectable formulation, SOP for lyophilizer operation, SOP for sterile filtration, SOP for sterilization validation, SOP for vial filling, SOP for visual inspection of injectables, Sterile area cleaning SOP, Sterile filling line SOP, Sterile injectable quality control SOP, Sterile injection SOP, Sterile manufacturing procedure

    Post navigation

    Previous Post: Gel Manufacturing: SOP for Identifying Degradation Products in Gels – V 2.0
    Next Post: Biosimilars: SOP for Risk Assessment in Upstream Failures – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Gels V 2.0
    • Injectables V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version